Minimally Invasive Glaucoma Surgery (MIGS) Devices Market To Reach $781.2 Million By 2030

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Growth & Trends

The global minimally invasive glaucoma surgery (MIGS) devices market size is anticipated to reach USD 781.2 million by 2030, registering a CAGR of 5.36% from 2024 to 2030, according to a new report by Grand View Research, Inc. The substantial factors propelling market growth include increasing awareness about minimally invasive surgery, technological advancements, the expanding geriatric population, and the continuous development of healthcare infrastructure.

An increasing number of medical device manufacturers are placing their focus on research and product development to introduce innovative products with greater precision and the potential to improve surgical outcomes. For instance, in August 2022, Glaukos received FDA clearance for the iStent infinite Trabecular Micro-Bypass System. The iStent Infinite is designed for use as a standalone procedure to lower elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma that remains uncontrolled despite previous medical and surgical treatments.

The development of new procedures, such as minimally invasive glaucoma surgery (MIGS), creates new opportunities in the market. Healthcare professionals increasingly prefer minimally invasive surgeries since they offer advantages such as smaller incisions, rapid wound healing, reduced pain, and smaller or no surgical scars. Smaller incisions & lower scope of complications can significantly reduce the overall surgery cost. According to the National Library of Medicine (NCBI), approximately 40,000 MIGS surgical procedures were performed in patients diagnosed with glaucoma in 2018. This minimally invasive surgery can reduce hospital stays, lowering the chance of patients contracting hospital-acquired infections. Shorter hospital stays also enable patients to return to their normal lives quicker.

The growing geriatric population, which is more susceptible to developing glaucoma, is expected to significantly contribute to the growth of the minimally invasive glaucoma surgery devices market. For instance, according to a Statistics Canada report, in 2022, about 7.32 million people, accounting for 18.8% of the general population, were aged 65 and above in Canada. As the elderly population continues to expand, there is a higher prevalence of age-related eye conditions, with glaucoma being one of the most common. Furthermore, the rising incidence of diabetes globally is expanding the population of individuals with glaucoma. Diabetes is a widely recognized risk factor for the onset and advancement of glaucoma. For instance, according to the international diabetes federation, in 2021 there were about 366 million adults with diabetes the number is further estimated to reach 783 million by 2045. Thus, the aforementioned factors contribute to the market growth.

 Request a free sample copy or view report summary: Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report Highlights

• Based on product, the glaucoma drainage implant segment dominated the market with a revenue share of over 33.18% in 2023. Moreover, the stent segment is anticipated to grow at the fastest CAGR during the forecast period

• Based on surgery method, the trabecular meshwork bypass segment held the largest market share in 2023. The Schlemm’s canal implants segment is expected to grow at the fastest CAGR during the forecast period

• Based on end-use, the hospitals segment captured most of the market share in 2023. Patient safety and surgical success are given top priority at hospitals, thus boosting segment growth

• North America dominated the market with a revenue share of above 35% in 2023

Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Segmentation

Grand View Research has segmented the global minimally invasive glaucoma surgery (MIGS) devices market, based on product, surgery method, end-use, and regions:

Minimally Invasive Glaucoma Surgery (MIGS) Devices Product Outlook (Revenue, USD Million, 2018 - 2030)

• Valves

• Glaucoma Drainage Implant

• Glaucoma Tube Shunts

• Stents

• Others

Minimally Invasive Glaucoma Surgery (MIGS) Devices Surgery Method Outlook (Revenue, USD Million, 2018 - 2030)

• Trabecular Meshwork Bypass

  • By Stent Placement

  • By Tissue Excision

• Suprachoroidal Space Implants

• Subconjunctival Space Implants

• Schlemm’s Canal Implants

• Gonioscopy-assisted Transluminal Trabeculectomy

• Endocyclophotocoagulation

Minimally Invasive Glaucoma Surgery (MIGS) Devices End-use Outlook (Revenue USD Million, 2018 - 2030)

• Hospitals

• Ophthalmic Clinics

• Others Surgical Centers

Minimally Invasive Glaucoma Surgery (MIGS) Devices Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Minimally Invasive Glaucoma Surgery (MIGS) Devices Market

• Alcon, Inc.

• Glaukos Corporation.

• Johnson & Johnson Vision

• AbbVie Inc. (Allergan Plc.)

• Corza Ophthalmology

• Carl Zeiss Meditec AG

• Katalyst Surgical

• Lumenis Ltd

• Ziemer Ophthalmic Systems AG

• Iridex Corporation